ERBB2 and breast cancer: Furthermore, LINC00589 has been found to sensitize HER2-positive breast cancer cells to trastuzumab and counteract cancer stem cell-like properties, as well as chemoresistance, to various agents including 5-Fluorouracil, doxorubicin, paclitaxel, cisplatin, gemcitabine, and vincristine24.